The future of Alzheimer’s disease therapies appears to remain dominated by amyloid beta A4 protein inhibitors. he number one component of activity (MoA) for the Alzheimer's illness (Promotion) pipeline is the hindrance of amyloid plaque arrangement. In any case, as per new exploration by the College of Cincinnati, amyloid plaques may not be the significant reason for Promotion as recently...